Logo image of KNSA

KINIKSA PHARMACEUTICALS INTE (KNSA) Stock Price, Quote, News and Overview

NASDAQ:KNSA - Nasdaq - GB00BRXB0C07 - Common Stock - Currency: USD

19.63  -0.39 (-1.95%)

After market: 19.63 0 (0%)

KNSA Quote, Performance and Key Statistics

KINIKSA PHARMACEUTICALS INTE

NASDAQ:KNSA (2/24/2025, 4:30:02 PM)

After market: 19.63 0 (0%)

19.63

-0.39 (-1.95%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High28.15
52 Week Low16.56
Market Cap1.42B
Shares72.20M
Float39.81M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE45.39
Earnings (Next)N/A N/A
IPO05-24 2018-05-24


KNSA short term performance overview.The bars show the price performance of KNSA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10 -15 -20 -25

KNSA long term performance overview.The bars show the price performance of KNSA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 40 60 80

The current stock price of KNSA is 19.63 USD. In the past month the price decreased by -2%. In the past year, price decreased by -9.71%.

KINIKSA PHARMACEUTICALS INTE / KNSA Daily stock chart

KNSA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.17 360.64B
AMGN AMGEN INC 15.63 166.32B
GILD GILEAD SCIENCES INC 24.08 138.34B
VRTX VERTEX PHARMACEUTICALS INC 1660.86 123.74B
REGN REGENERON PHARMACEUTICALS 15.63 77.97B
ARGX ARGENX SE - ADR N/A 38.04B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.11B
BNTX BIONTECH SE-ADR N/A 28.04B
ONC BEIGENE LTD-ADR N/A 27.58B
NTRA NATERA INC N/A 20.91B
BIIB BIOGEN INC 8.58 20.59B
UTHR UNITED THERAPEUTICS CORP 15.73 15.99B

About KNSA

Company Profile

KNSA logo image Kiniksa Pharmaceuticals Ltd is a BM-based company operating in Biotechnology industry. Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The firm is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).

Company Info

KINIKSA PHARMACEUTICALS INTE

Clarendon House, 2 Church Street

Hamilton HM11 BM

CEO: Sanj K. Patel

Employees: 297

Company Website: https://www.kiniksa.com/

Investor Relations: https://investors.kiniksa.com/

Phone: 7814399100

KINIKSA PHARMACEUTICALS INTE / KNSA FAQ

What is the stock price of KINIKSA PHARMACEUTICALS INTE today?

The current stock price of KNSA is 19.63 USD. The price decreased by -1.95% in the last trading session.


What is the ticker symbol for KINIKSA PHARMACEUTICALS INTE stock?

The exchange symbol of KINIKSA PHARMACEUTICALS INTE is KNSA and it is listed on the Nasdaq exchange.


On which exchange is KNSA stock listed?

KNSA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for KINIKSA PHARMACEUTICALS INTE stock?

12 analysts have analysed KNSA and the average price target is 36.72 USD. This implies a price increase of 87.06% is expected in the next year compared to the current price of 19.63. Check the KINIKSA PHARMACEUTICALS INTE stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is KINIKSA PHARMACEUTICALS INTE worth?

KINIKSA PHARMACEUTICALS INTE (KNSA) has a market capitalization of 1.42B USD. This makes KNSA a Small Cap stock.


How many employees does KINIKSA PHARMACEUTICALS INTE have?

KINIKSA PHARMACEUTICALS INTE (KNSA) currently has 297 employees.


What are the support and resistance levels for KINIKSA PHARMACEUTICALS INTE (KNSA) stock?

KINIKSA PHARMACEUTICALS INTE (KNSA) has a support level at 19.94 and a resistance level at 20.03. Check the full technical report for a detailed analysis of KNSA support and resistance levels.


Is KINIKSA PHARMACEUTICALS INTE (KNSA) expected to grow?

The Revenue of KINIKSA PHARMACEUTICALS INTE (KNSA) is expected to grow by 65.23% in the next year. Check the estimates tab for more information on the KNSA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy KINIKSA PHARMACEUTICALS INTE (KNSA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does KINIKSA PHARMACEUTICALS INTE (KNSA) stock pay dividends?

KNSA does not pay a dividend.


What is the Price/Earnings (PE) ratio of KINIKSA PHARMACEUTICALS INTE (KNSA)?

KINIKSA PHARMACEUTICALS INTE (KNSA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.14).


What is the Short Interest ratio of KINIKSA PHARMACEUTICALS INTE (KNSA) stock?

The outstanding short interest for KINIKSA PHARMACEUTICALS INTE (KNSA) is 4.85% of its float. Check the ownership tab for more information on the KNSA short interest.


KNSA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to KNSA. When comparing the yearly performance of all stocks, KNSA is a bad performer in the overall market: 66.97% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

KNSA Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to KNSA. KNSA has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

KNSA Financial Highlights

Over the last trailing twelve months KNSA reported a non-GAAP Earnings per Share(EPS) of -0.14. The EPS decreased by -27.27% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -1.63%
ROE -2.08%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%10%
Sales Q2Q%67.37%
EPS 1Y (TTM)-27.27%
Revenue 1Y (TTM)54.41%

KNSA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to KNSA. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of -366.33% and a revenue growth 65.23% for KNSA


Ownership
Inst Owners96.6%
Ins Owners4.2%
Short Float %4.85%
Short Ratio3.92
Analysts
Analysts85
Price Target36.72 (87.06%)
EPS Next Y-366.33%
Revenue Next Year65.23%